European Union - English - EMA (European Medicines Agency)

ecuphar nv - enflicoxib - antiinflammatory and antirheumatic products - dogs - for the treatment of pain and inflammation associated with osteoarthritis (or degenerative joint disease) in dogs.

United Kingdom - English - VMD (Veterinary Medicines Directorate)

ecuphar nv - enflicoxib - tablet - anti inflammatory nsaid - dogs

United Kingdom - English - VMD (Veterinary Medicines Directorate)

ecuphar nv - enflicoxib - tablet - anti inflammatory nsaid - dogs

United Kingdom - English - VMD (Veterinary Medicines Directorate)

ecuphar nv - enflicoxib - tablet - anti inflammatory nsaid - dogs

United Kingdom - English - VMD (Veterinary Medicines Directorate)

ecuphar nv - enflicoxib - tablet - anti inflammatory nsaid - dogs

United Kingdom - English - VMD (Veterinary Medicines Directorate)

ecuphar nv - enflicoxib - tablet - anti inflammatory nsaid - dogs

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - etoricoxib - film coated tablet - 30 milligram - coxibs - antiinflammatory and antirheumatic products, non-steroids, coxibs - etoricoxib is indicated in adults and adolescents 16 years of age and older for the symptomatic relief of osteoarthritis (oa), rheumatoid arthritis (ra), ankylosing spondylitis, and the pain and signs of inflammation associated with acute gouty arthritis. etoricoxib is indicated in adults and adolescents 16 years of age and older for the short-term treatment of moderate pain associated with dental surgery. the decision to prescribe a selective cyclooxygenase-2 (cox-2) inhibitor should be based on an assessment of the individual patient's overall risks

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - etoricoxib - film coated tablet - 60 milligram - coxibs - antiinflammatory and antirheumatic products, non-steroids, coxibs - etoricoxib is indicated in adults and adolescents 16 years of age and older for the symptomatic relief of osteoarthritis (oa), rheumatoid arthritis (ra), ankylosing spondylitis, and the pain and signs of inflammation associated with acute gouty arthritis. etoricoxib is indicated in adults and adolescents 16 years of age and older for the short-term treatment of moderate pain associated with dental surgery. the decision to prescribe a selective cyclooxygenase-2 (cox-2) inhibitor should be based on an assessment of the individual patient's overall risks

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - etoricoxib - film coated tablet - 90 milligram - coxibs - antiinflammatory and antirheumatic products, non-steroids, coxibs - etoricoxib is indicated in adults and adolescents 16 years of age and older for the symptomatic relief of osteoarthritis (oa), rheumatoid arthritis (ra), ankylosing spondylitis, and the pain and signs of inflammation associated with acute gouty arthritis. etoricoxib is indicated in adults and adolescents 16 years of age and older for the short-term treatment of moderate pain associated with dental surgery. the decision to prescribe a selective cyclooxygenase-2 (cox-2) inhibitor should be based on an assessment of the individual patient's overall risks

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - etoricoxib - film coated tablet - 120 milligram - coxibs - antiinflammatory and antirheumatic products, non-steroids, coxibs - etoricoxib is indicated in adults and adolescents 16 years of age and older for the symptomatic relief of osteoarthritis (oa), rheumatoid arthritis (ra), ankylosing spondylitis, and the pain and signs of inflammation associated with acute gouty arthritis. etoricoxib is indicated in adults and adolescents 16 years of age and older for the short-term treatment of moderate pain associated with dental surgery. the decision to prescribe a selective cyclooxygenase-2 (cox-2) inhibitor should be based on an assessment of the individual patient's overall risks